tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRDN Stock Latest News

Viridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market
RatingsViridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market
11h ago
VRDN
Underwhelming Roche data helps Veridian’s position in TED, says Jefferies
PremiumThe Fly
Underwhelming Roche data helps Veridian’s position in TED, says Jefferies
11h ago
CHRO
VRDN
Viridian Therapeutics Positioned for Success Amid Competitive Challenges in TED Market
PremiumRatings
Viridian Therapeutics Positioned for Success Amid Competitive Challenges in TED Market
17h ago
VRDN
Buy Rating Affirmed for Viridian Therapeutics Amid Promising Developments in Thyroid Eye Disease Treatment
PremiumRatings
Buy Rating Affirmed for Viridian Therapeutics Amid Promising Developments in Thyroid Eye Disease Treatment
1d ago
VRDN
Viridian Therapeutics’ Veligrotug Outperforms Roche’s Satralizumab in TED Treatment, Supporting Buy Rating
PremiumRatings
Viridian Therapeutics’ Veligrotug Outperforms Roche’s Satralizumab in TED Treatment, Supporting Buy Rating
1d ago
VRDN
Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook
PremiumRatingsViridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook
24d ago
VRDN
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics
Premium
Ratings
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics
1M ago
VRDN
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial Position
Premium
Ratings
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial Position
1M ago
VRDN
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
1M ago
VRDN
Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studies
PremiumThe Fly
Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studies
1M ago
VRDN
Viridian Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Viridian Therapeutics files automatic mixed securities shelf
1M ago
VRDN
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
2M ago
VRDN
Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
PremiumThe FlyViridian Therapeutics price target raised to $32 from $28 at Oppenheimer
2M ago
AMGN
VRDN
Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
Premium
Ratings
Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
2M ago
VRDN
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo
Premium
The Fly
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo
2M ago
VRDN
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
PremiumRatings
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
2M ago
VRDN
Viridian Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Viridian Therapeutics Reports Q2 2025 Financial Results
2M ago
VRDN
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
PremiumRatings
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
2M ago
VRDN
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
PremiumRatings
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
2M ago
VRDN
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments
PremiumRatingsViridian Therapeutics: Promising Future with Strong Financials and Strategic Developments
2M ago
VRDN
Viridian Therapeutics reports Q2 EPS ($1.00), consensus (97c)
Premium
The Fly
Viridian Therapeutics reports Q2 EPS ($1.00), consensus (97c)
2M ago
VRDN
Viridian Therapeutics: Strategic Partnership and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
Viridian Therapeutics: Strategic Partnership and Promising Clinical Developments Drive Buy Rating
3M ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >